Nuvalent (NUVL) Competitors $70.78 +0.78 (+1.11%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$70.80 +0.02 (+0.03%) As of 04/15/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVL vs. TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, and ROIVShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Nuvalent vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Nuvalent (NASDAQ:NUVL) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals & insiders hold more shares of NUVL or TEVA? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 12.5% of Nuvalent shares are held by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer NUVL or TEVA? Teva Pharmaceutical Industries received 1289 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.95% of users gave Nuvalent an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformNuvalentOutperform Votes4578.95% Underperform Votes1221.05% Teva Pharmaceutical IndustriesOutperform Votes133467.82% Underperform Votes63332.18% Which has more risk & volatility, NUVL or TEVA? Nuvalent has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Is NUVL or TEVA more profitable? Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -28.63% -27.15% Teva Pharmaceutical Industries -9.91%42.46%6.65% Does the media prefer NUVL or TEVA? In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Nuvalent. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 5 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.22 beat Teva Pharmaceutical Industries' score of 1.13 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Teva Pharmaceutical Industries 15 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, NUVL or TEVA? Nuvalent has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Nuvalent is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$126.22M-$3.90-18.15Teva Pharmaceutical Industries$16.54B0.93-$1.64B-$1.45-9.37 Do analysts recommend NUVL or TEVA? Nuvalent presently has a consensus price target of $113.44, indicating a potential upside of 60.28%. Teva Pharmaceutical Industries has a consensus price target of $23.43, indicating a potential upside of 72.46%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryNuvalent beats Teva Pharmaceutical Industries on 10 of the 18 factors compared between the two stocks. Remove Ads Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.07B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-20.406.7921.7317.81Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book6.475.866.464.00Net Income-$126.22M$141.86M$3.20B$247.23M7 Day Performance9.40%4.50%2.85%1.45%1 Month Performance-8.09%-12.65%-8.55%-6.24%1 Year Performance9.31%-11.06%10.46%0.60% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent1.9873 of 5 stars$70.78+1.1%$113.44+60.3%+8.4%$5.07BN/A-20.4040Positive NewsTEVATeva Pharmaceutical Industries3.0326 of 5 stars$13.91+0.8%$23.43+68.5%+2.7%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4948 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6134 of 5 stars$17.32-0.2%$35.40+104.4%+573.6%$12.78B$700,000.00-61.85110News CoverageGMABGenmab A/S4.2091 of 5 stars$18.19-1.1%$41.33+127.2%-33.9%$12.04B$21.53B10.451,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.3519 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800High Trading VolumeMRNAModerna4.259 of 5 stars$25.64+2.1%$59.00+130.1%-74.7%$9.91B$3.20B-2.763,900Gap DownVTRSViatris2.9677 of 5 stars$7.61-0.1%$10.50+38.0%-33.9%$9.08B$14.74B-10.2837,000News CoverageHigh Trading VolumeQGENQiagen3.483 of 5 stars$40.33+5.4%$47.71+18.3%+7.7%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3142 of 5 stars$140.14-1.8%$204.64+46.0%+6.0%$8.50B$363.64M-19.741,017News CoveragePositive NewsGap DownROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies TEVA Competitors ITCI Competitors SMMT Competitors GMAB Competitors RDY Competitors MRNA Competitors VTRS Competitors QGEN Competitors ASND Competitors ROIV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NUVL) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NUVL Stock Free NUVL Stock Alerts